Patents by Inventor Matilde Sanchez

Matilde Sanchez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12377071
    Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta [b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.
    Type: Grant
    Filed: January 8, 2024
    Date of Patent: August 5, 2025
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Alan Glicklich, Maria Matilde Sanchez Kam, William R. Shanahan
  • Publication number: 20250186409
    Abstract: The invention relates to a 5-aminohexahydro-6,7,8-trihydroxy-3H-oxazo-lo[3,4-a]pyridin-3-one (i.e. 2,3,4-trihydroxy-5N,6O-oxomethylidene-nojirimycin-1-amine) glycol-ipid mimetic derivative of formula (I) acting as antagonists or agonist of the TLR4 for the treatment and/or prevention of an immune disease such as e.g. acute inflammation, chronic disease allergy, the Metabolic Syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), immune mediated hepatitis, an autoimmune disease, graft rejection pathology, inflammatory bowel disease, atherosclerosis and airway hyperactivity, such as e.g. asthma and allergic rhinitis. An exemplary compound is e.g. example 1, compound (1).
    Type: Application
    Filed: October 26, 2022
    Publication date: June 12, 2025
    Inventors: José Manuel GARCÍA FERNÁNDEZ, Carmen ORTIZ MELLET, Manuel GONZÁLEZ CUESTA, Elena Matilde SÁNCHEZ FERNÁNDEZ, Ya-Jen CHANG, Alan Chuan-Ying LAI
  • Publication number: 20240180870
    Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta [b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.
    Type: Application
    Filed: January 8, 2024
    Publication date: June 6, 2024
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: Alan Glicklich, Maria Matilde Sanchez Kam, William R. Shanahan
  • Patent number: 11896578
    Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: February 13, 2024
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Alan Glicklich, Maria Matilde Sanchez Kam, William R. Shanahan
  • Publication number: 20210338636
    Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.
    Type: Application
    Filed: April 20, 2021
    Publication date: November 4, 2021
    Inventors: Alan Glicklich, Maria Matilde Sanchez Kam, William R. Shanahan
  • Patent number: 11007175
    Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoro-methyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: May 18, 2021
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Alan Glicklich, Maria Matilde Sanchez Kam, William R. Shanahan
  • Publication number: 20180263958
    Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoro-methyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.
    Type: Application
    Filed: January 16, 2016
    Publication date: September 20, 2018
    Inventors: Alan GLICKLICH, Maria Matilde Sanchez KAM, William R. SHANAHAN
  • Publication number: 20170239263
    Abstract: Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual.
    Type: Application
    Filed: October 6, 2016
    Publication date: August 24, 2017
    Inventors: Matilde Sanchez, William R. Shanahan
  • Patent number: 9169213
    Abstract: Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: October 27, 2015
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Matilde Sanchez, William R. Shanahan
  • Publication number: 20150297610
    Abstract: Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual.
    Type: Application
    Filed: November 6, 2012
    Publication date: October 22, 2015
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: Matilde Sanchez, William R. Shanahan
  • Patent number: 9112548
    Abstract: A method to optimize the power assignment of user streams transmitted from base stations in coordinated base station transmission systems. In the method of the invention said CBST systems employ block diagonalization techniques and are deployed in MIMO-OFDM scenarios, and it further comprises using a new waterfilling technique which provides a performance very close to the theoretical ideal but with a reduced computational complexity.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: August 18, 2015
    Assignee: Telefonica, S.A.
    Inventors: Ana Garcia Armada, Ma Luz Pablo Gonzalez, Matilde Sanchez Fernandez, Roberto Corvaja, Ignacio Berberana Fernandez Murias
  • Publication number: 20150023442
    Abstract: A method to optimize the power assignment of user streams transmitted from base stations in coordinated base station transmission systems. In the method of the invention said CBST systems employ block diagonalization techniques and are deployed in MIMO-OFDM scenarios, and it further comprises using a new waterfilling technique which provides a performance very close to the theoretical ideal but with a reduced computational complexity.
    Type: Application
    Filed: July 6, 2012
    Publication date: January 22, 2015
    Applicant: TELEFONICA, S.A.
    Inventors: Ana Garcia Armada, Ma Luz Pablo Gonzalez, Matilde Sanchez Fernandez, Roberto Corvaja, Ignacio Berberana Fernandez Murias
  • Publication number: 20140213579
    Abstract: Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual.
    Type: Application
    Filed: April 1, 2014
    Publication date: July 31, 2014
    Inventors: Matilde Sanchez, William R. Shanahan